- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02579590
The Female Sexual Functions With Progestogen-only Contraception
Evaluation of Female Sexual Functions in Progestogen-only Contraceptive Users
Female sexual dysfunction is age-related, progressive, and very common condition. The physiology of the female sexual function is a complex condition affected by emotional, medical and hormonal elements.
Progestogen-only contraception relies on progestogens alone to achieve contraception. There are several progestogen only contraceptive methods include progestogen only pill (minipill), subdermal implants, Depo-Provera (DMPA) and levonorgestrel intrauterine system. Many studies in literature reported the negative effect of combined oral contraceptive pills (COCs) on female sexual function due to decrease in bioavailability of testosterone and increase level of sex hormone binding globulin (SHBG) which leads to decrease in free testosterone level contributes to dysfunction.
However, the progesterone only methods contains no estrogen, so it has less effect on sex hormone binding globulin and therefore less effect on free testosterone. DMPA (injectable progestins) is an injectable progestin is a highly reliable form of contraception. Nelson in 1996 found that about 6% of women using DMPA reported either lost or decreased libido. More recent study by Fortenberry in 2011 reported that DMPA had no effect on sexual interest compared with nonusers of any hormonal method of contraception in an adolescent population. The etonogestrel implant (Implanon) is a single rod that is inserted into the medial side of non dominant upper arm. Although in general, it is very effective and has relatively low side effect, a decreased libido has been noted.
Cerazette is a progestogen-only contraceptive pill containing 75 micrograms of desogestrel. It acts mainly by inhibiting ovulation. Cerazette users also may complain of decreased libido.
The estrogen is the main hormone which responsible for vitality of the pelvic organ especially the vagina. The main mechanism of action of the DMPA, Implanon and Cerazette is inhibition of ovulation, which leads to decrease in the estrogen level, which causes a drop in blood flow in uterine artery and accordingly the vagina artery. That can affect vaginal lubrication, causing the vagina to be too dry for comfortable sex.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Assiut, Egypt, 71111
- Assiut University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient aged between 20-45 years old.
- Sexually active women with regular marital life.
- Using DMPA, Implanon or Cerazette for at least 6 months and no more than 12 months.
- Using the above method only for pregnancy prevention.
- Have not any medical or gynaecologic problem.
Exclusion Criteria:
- Lactating women
- Women have abnormal uterine bleeding with contraception
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
DEMPA group
This group are using DMPA (Depot Medroxyprogesterone Acetate 150 mg) injection every 3 month for 6-12 month
|
the DMPA user" where they are using Depot Medroxyprogesterone Acetate 150 mg (DMPA; Phrmcia) injection every 3 month
|
Implanon group
This group are using "Implanon " (etonogestrel implant) 68 mg implant for 6-12 month
|
where they are using etonogestrel 68 mg implant (Implanon; Organon)
|
Cerazette group
This group are using Cerazette pills (75 micrograms desogestrel) one pill every day for 28 days without pill-free interval for 6-12 month.
|
where they are using desogestrel 75 micrograms (Cerazette; Organon), one pill every day for 28 days without pill-free interval.
|
Normal healthy group
Those women not using any method of contraception
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Female Sexual function
Time Frame: 6 months
|
The investigators will assess the female sexual function by Arabic Female Sexual Function Index (AFSFI) which is a brief and validated questionnaire designed to assess the sexual functioning in a many Arabic countries during the past month.
if the score < 28.1; this will mean female sexual dysfunction
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mohammed K Ali, MD, Assiut University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Antineoplastic Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptives, Oral
- Contraceptive Agents, Female
- Contraceptives, Oral, Synthetic
- Contraceptives, Oral, Hormonal
- Progestins
- Contraceptive Agents, Male
- Medroxyprogesterone Acetate
- Medroxyprogesterone
- Desogestrel
- Etonogestrel
Other Study ID Numbers
- AFSFI
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Female Sexual Function
-
Karabuk UniversityRecruitingAnxiety | Sexual Dysfunction | High Risk Pregnancy | Female Sexual FunctionTurkey
-
University of SaskatchewanCanadian Institutes of Health Research (CIHR)Completed
-
Shixuan WangSun Yat-sen University; Huazhong University of Science and Technology; Shanghai... and other collaboratorsUnknownCardiovascular Diseases | Menopausal Syndrome | Female Infertility Due to Diminished Ovarian Reserve | Sexual Function and Fertility DisordersChina
-
Cairo UniversityUnknownSexual Function Disturbances | Urinary Function DisordersEgypt
-
ART Fertility Clinics LLCOrganon and CoRecruitingInfertility | Fertility Issues | Infertility,Female | Ovarian Function InsufficiencyUnited Arab Emirates
-
Cardenal Herrera UniversityNot yet recruitingBody Image | Female Sexual Function | Self Esteem | Intimacy With Your Partner
-
Chulalongkorn UniversityRecruitingVulvovaginal Atrophy | Postmenopausal Atrophic Vaginitis | Female Sexual FunctionThailand
-
Bahceci Health GroupUskudar UniversityUnknownWomen's Quality of Life, Sexual Life and Psychological State in Patients Undergoing Embryo TransfersDepression | Quality of Life | Anxiety State | Infertility, Female | Sexual Function and Fertility DisordersTurkey
-
Kanuni Sultan Suleyman Training and Research HospitalCompleted
Clinical Trials on Depot Medroxyprogesterone Acetate 150 mg
-
AbbottFraktal.com.pl; Med-net.plCompletedLower Urinary Tract Symptoms | Advanced Prostate CancerPoland, Ukraine
-
Mahidol UniversityCompleted
-
Chulalongkorn UniversityCompletedClinically Diagnosed Endometriotic Patient Was Defined as a Woman Who Has Pelvic Pain and at Least One Evidence of PV or TVS
-
Beatrice ChenSociety of Family PlanningCompletedPostpartum Depression | Contraception | LactationUnited States
-
AIDS Clinical Trials GroupNational Institute of Allergy and Infectious Diseases (NIAID)CompletedTuberculosis | HIV-1 InfectionSouth Africa, Zimbabwe, Botswana, Kenya
-
Assiut UniversityRecruiting
-
Women and Infants Hospital of Rhode IslandUnknownGrade 1 Endometrial Endometrioid Adenocarcinoma | Grade 2 Endometrial Endometrioid Adenocarcinoma | Complex Atypical Endometrial HyperplasiaUnited States
-
Emory UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingHormonal ContraceptionUnited States
-
Northwestern UniversitySociety of Family PlanningRecruitingContraceptionUnited States